Unknown

Dataset Information

0

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma


ABSTRACT: Abstract

Background

There is an urgent need for effective treatments against glioblastoma (GBM). In this trial, we investigated the efficacy and safety of an adoptive cell-based immunotherapy.

Methods

Patients with newly diagnosed GBM were recruited at 4 study sites in Sweden. The patients were randomized 1:2 to receive either radiotherapy (RT), 60 Gy/30 fractions, with concomitant and adjuvant temozolomide (TMZ) only, or RT and TMZ with the addition of Autologous Lymphoid Effector Cells Specific Against Tumor (ALECSAT) in an open-label phase II trial. The primary endpoint was investigator-assessed progression-free survival (PFS). The secondary endpoints were survival and safety of ALECSAT.

Results

Sixty-two patients were randomized to either standard of care (SOC) with RT and TMZ alone (n = 22) or SOC with ALECSAT (n = 40). Median age was 57 years (range 38–69), 95% of the patients were in good performance status (WHO 0–1). There was no significant difference between the study arms (SOC vs ALECSAT + SOC) in PFS (7.9 vs 7.8 months; hazard ratio [HR] 1.28; 95% confidence interval [CI] 0.70–2.36; P = .42) or in median overall survival (OS) (18.3 vs 19.2 months; HR 1.16, 95% CI 0.58–2.31; P = .67). The treatment groups were balanced in terms of serious adverse events (52.4% vs 52.5%), but adverse events ≥grade 3 were more common in the experimental arm (81.0% vs 92.5%).

Conclusion

Addition of ALECSAT immunotherapy to standard treatment with radiochemotherapy was well tolerated but did not improve PFS or OS for patients with newly diagnosed GBM.

SUBMITTER: Werlenius K 

PROVIDER: S-EPMC8577524 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4523080 | biostudies-literature
| S-EPMC4896538 | biostudies-literature
| S-EPMC9139576 | biostudies-literature
| S-EPMC4588750 | biostudies-literature
| S-EPMC5570193 | biostudies-literature
| S-EPMC4319643 | biostudies-literature
| S-EPMC8674255 | biostudies-literature
| S-EPMC2749868 | biostudies-literature
| S-EPMC8496728 | biostudies-literature
| S-EPMC5423504 | biostudies-literature